The FDA has expanded the use of ustekinumab injection (Stelara, Janssen) for subcutaneous use to treat pediatric patients 6 years and older with psoriatic arthritis (PsA). Ustekinumab was approved for the same indication for adults in 2013.
Ustekinumab is a fully human monoclonal antibody that selectively inhibits both interleukin (IL)-12 and IL-23, two cytokines thought to play an important role in tempering the overactive inflammatory response in several autoimmune diseases. Ustekinumab